Eli Lilly Unfunded Venture Capital Commitments increased by 5.1% to $878.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 5.1%, from $925.00M to $878.00M.
unfunded_venture_capital_commitments| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $758.00M | $781.00M | $843.00M | $980.00M | $854.00M | $950.00M | $925.00M | $915.00M | $880.00M | $900.00M | $925.00M | $868.00M | $835.00M | $878.00M |
| QoQ Change | — | +3.0% | +7.9% | +16.3% | -12.9% | +11.2% | -2.6% | -1.1% | -3.8% | +2.3% | +2.8% | -6.2% | -3.8% | +5.1% |
| YoY Change | — | — | — | +29.3% | +9.3% | +12.7% | -5.6% | +7.1% | -7.4% | -2.7% | +1.1% | -1.4% | -7.2% | -5.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.